Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14127541 | 0.85 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL167090 | 0.85 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29558143 | 0.85 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7403167 | 0.83 | CA12 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9383598 | 0.79 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12003966 | 0.78 | CA12 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8035636 | 0.77 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1697477 | 0.76 | KDM4E (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7792001 | 0.76 | CA12 (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31254048 | 0.76 | CA12 (0.42) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518975-B2 | Gamma secretase modulators | Merck Sharp + Dohme Corp. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518975-B2 | Gamma secretase modulators | Merck Sharp + Dohme Corp. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-27 | — | — | US | disclosed |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-27 | — | — | US | disclosed |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-20 | — | — | US | disclosed |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-20 | — | — | US | disclosed |
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-09-13 | — | — | US | disclosed |
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-09-13 | — | — | US | disclosed |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-04-07 | — | — | US | disclosed |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-04-07 | — | — | US | disclosed |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION | 2011-02-03 | — | — | US | disclosed |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION | 2011-02-03 | — | — | US | disclosed |
| WO-2010147969-A2 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147975-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147973-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2009032277-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CA12 3633/4885CA1 615/4885CA2 3455/4885 |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CA12 3633/4885CA1 615/4885CA2 3455/4885 |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CA12 3742/4885CA1 794/4885CA2 3696/4885 |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | CA12 3151/4885CA1 513/4885CA2 2888/4885 |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CA12 3651/4885CA1 727/4885CA2 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.